<code id='C644CA1F4E'></code><style id='C644CA1F4E'></style>
    • <acronym id='C644CA1F4E'></acronym>
      <center id='C644CA1F4E'><center id='C644CA1F4E'><tfoot id='C644CA1F4E'></tfoot></center><abbr id='C644CA1F4E'><dir id='C644CA1F4E'><tfoot id='C644CA1F4E'></tfoot><noframes id='C644CA1F4E'>

    • <optgroup id='C644CA1F4E'><strike id='C644CA1F4E'><sup id='C644CA1F4E'></sup></strike><code id='C644CA1F4E'></code></optgroup>
        1. <b id='C644CA1F4E'><label id='C644CA1F4E'><select id='C644CA1F4E'><dt id='C644CA1F4E'><span id='C644CA1F4E'></span></dt></select></label></b><u id='C644CA1F4E'></u>
          <i id='C644CA1F4E'><strike id='C644CA1F4E'><tt id='C644CA1F4E'><pre id='C644CA1F4E'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:6
          Jim Mone/AP

          The U.S. Department of Labor claims in a new lawsuit that a UnitedHealth Group unit illegally rejected emergency room care and urine drug screen claims for thousands of people.

          UMR, Inc., a Wisconsin-based third-party administrator owned by UnitedHealth, manages benefits for more than 2,100 employee health plans. The federal government says the company denied ER visits and urine drug screens for years using a process that didn’t meet federal standards for health plans that employers fund themselves, known as self-insured plans. The standards are part of a law called the Employee Retirement Income Security Act, or ERISA.

          advertisement

          “I see it as significant because the Department of Labor is actually looking under the hood at the standards and methods that insurers apply when they decide whether or not to approve or deny a claim,” said Colleen Medill, a professor at the University of Nebraska College of Law and nationally recognized legal scholar on ERISA. “They are looking at their process.”

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Caribou posts encouraging results on off
          Caribou posts encouraging results on off

          RachelHaurwitz,CEOofCaribouBiosciences.ElizabethD.HermanforSTATCaribouBiosciencessaidThursdaythatits

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Pfizer plans to depart BIO

          Pfizerplanstoexitamajorbiotechnologyindustrytradeassociation.CindyOrd/GettyImagesforPfizer/BioNTechW